Ventricular extrasystoles – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 12 Aug 2026 04:13:50 +0000 en-US hourly 1 https://wordpress.org/?v=7.1 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Ventricular extrasystoles – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Flecainide versus Bisoprolol as First-Line Treatment for Premature Ventricular Contractions in Adult Patients: A Multicenter Randomized Trial https://clinicaltrials.eu/trial/flecainide-versus-bisoprolol-as-first-line-treatment-for-premature-ventricular-contractions-in-adult-patients-a-multicenter-randomized-trial/ Wed, 12 Aug 2026 04:13:50 +0000 https://clinicaltrials.eu/trial/flecainide-versus-bisoprolol-as-first-line-treatment-for-premature-ventricular-contractions-in-adult-patients-a-multicenter-randomized-trial/ The study focuses on people who experience Premature Ventricular Contractions, which are extra heartbeats that start in the lower chambers of the heart and can cause a feeling of skipped beats or fluttering. Two oral medicines are being compared as first‑line treatment: flecainide, which works by slowing the electrical signals that cause these extra beats, and bisoprolol, a beta‑blocker that reduces heart rate and the force of contraction. The purpose of the study is to determine which medication more effectively reduces the number of extra beats.

Participants will take the assigned medication for about three months. Their heart rhythm will be recorded using a portable device called a Holter-ECG, which continuously monitors the heart’s electrical activity for a week at the start of the study and again after three months. In addition, participants will answer simple questionnaires that measure overall well‑being, including the EQ-5D visual scale and the SF-12 health survey, to see how the treatment impacts daily life.

Throughout the study, any side effects such as fatigue, dizziness, low blood pressure, or more serious heart problems will be recorded. The need for additional procedures, such as a catheter-based technique to destroy the source of the extra beats, will also be noted. The overall goal is to find the safer and more effective option for managing these premature heartbeats.

]]> Study of drug combination therapy in asymptomatic patients with frequent premature ventricular contractions and normal heart function to prevent left ventricular dysfunction https://clinicaltrials.eu/trial/study-on-the-effect-of-verapamil-and-drug-combination-on-heart-function-in-asymptomatic-patients-with-frequent-premature-ventricular-complexes/ Mon, 03 Aug 2026 10:28:38 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-verapamil-and-drug-combination-on-heart-function-in-asymptomatic-patients-with-frequent-premature-ventricular-complexes/ This study focuses on patients with premature ventricular complexes (PVCs), which are extra, abnormal heartbeats that begin in the heart’s lower chambers. The study specifically looks at people who have frequent PVCs (more than 10% of total heartbeats) but don’t feel any symptoms and have normal heart function. Several medications will be tested including verapamil, nebivolol, amiodarone, propafenone, bisoprolol, diltiazem, flecainide, and sotalol.

The purpose is to determine if treating patients who have frequent PVCs but no symptoms can prevent future heart problems better than simply monitoring them without treatment. The study will last for 24 months, during which patients may receive medication or, if necessary, a procedure called ablation (which uses heat to destroy small areas of heart tissue causing irregular rhythms) if medications alone don’t reduce the PVCs enough.

Throughout the study, doctors will monitor how well the heart is pumping blood using special imaging tests like cardiac magnetic resonance imaging (cMRI) or heart ultrasound. They will also track changes in heart function, measure exercise capacity, and monitor for any side effects from the treatments.

]]> Comparison of Carvedilol and Flecainide Treatment in Patients with Idiopathic Ventricular Arrhythmias https://clinicaltrials.eu/trial/study-comparing-carvedilol-and-flecainide-for-patients-with-idiopathic-ventricular-arrhythmias/ Mon, 03 Aug 2026 10:24:34 +0000 https://clinicaltrials.eu/trial/study-comparing-carvedilol-and-flecainide-for-patients-with-idiopathic-ventricular-arrhythmias/ This clinical trial focuses on idiopathic ventricular arrhythmias, a heart condition where the heart beats irregularly without a known cause. The study compares two medications: carvedilol and flecainide, which are taken as oral tablets to treat irregular heart rhythms. The purpose is to determine which medication is more effective in reducing irregular heartbeats.

Participants will receive either carvedilol (up to 50 mg daily) or flecainide (up to 300 mg daily) for a period of 12 months. During the study, heart activity will be monitored using a Holter-ECG, which is a portable device that records heart rhythms over 24 hours. The recordings will be taken before starting treatment and after completing it.

The study will also look at how these medications affect overall quality of life and heart function. Heart function will be evaluated using echocardiography, a test that uses sound waves to create pictures of the heart. The study will track any side effects that participants may experience during the treatment period.

]]>